INTRODUCTION {#s1}
============

Gastric cancer is the second most common malignant disease and cause of cancer-related death worldwide, especially in developing countries \[[@R1]\]. Predicting clinical outcomes for gastric cancer patients can be challenging due to genetic and geographically-dependent differences in incidence, stage at treatment, and patient prognosis \[[@R2]\]. However, accurate prediction of prognosis is crucial for selecting therapeutic strategies and for effective communication between doctors and gastric cancer patients.

Generally, prognostic evaluations in gastric cancer are based mainly on the tumor-node-metastasis (TNM) staging system. However, due to constraints associated with maintaining its simplicity and uniformity, the TNM staging system does not take into account many essential variables, including patient characteristics, laboratory test results, and treatments administered, that can influence the survival of gastric cancer patients \[[@R3]\]. The TNM staging system is therefore limited in its ability to assess survival in these patients, and survival predictions can vary widely for each gastric cancer stage \[[@R4]\]. Nomograms have been increasingly used to more accurately predict individualized patient outcomes in a variety of cancers. However, few nomograms have been developed that predict clinical outcomes for gastric cancer patients.

Serum bilirubin, which is an end product of heme metabolism, was not thought to serve any physiological function. Nevertheless, recent studies have demonstrated that serum bilirubin has potent antioxidant, anti-inflammatory, and anticancer effects in colorectal cancer \[[@R5], [@R6]\]. The protective effects of serum bilirubin have been reported in lung cancer \[[@R7], [@R8]\], colorectal cancer \[[@R9]\], and breast cancer \[[@R10]\]. Additionally, decreased levels of albumin, a factor commonly used as an indicator of nutritional status, are associated with worse outcomes in gastric cancer patients \[[@R11]\].

Although they might improve prognostic predictions in gastric cancer, no measurements or indices that combine serum bilirubin and albumin levels have been developed. In this study, we examined whether serum bilirubin and albumin levels were predictive of survival outcomes in gastric cancer patients. We then evaluated the predictive value of a nomogram based on serum bilirubin and albumin levels in these patients.

RESULTS {#s2}
=======

Baseline characteristics {#s2_1}
------------------------

Baseline characteristics for the two patient cohorts are summarized in Table [1](#T1){ref-type="table"}. A total of 352 men and 127 women were prospectively enrolled in the training cohort. Of these patients, 180 (37.6%) had distant metastasis and 275 (57.4%) received chemotherapy. During the follow-up period, 298 (62.2%) patients died (median follow-up, 1156 days). The median values for TBIL, DBIL, IDBIL, and albumin were 10.1 μmol/L, 3.6 μmol/L, 6.3 μmol/L, and 37.1 g/L, respectively. An additional 299 patients were retrospectively enrolled in the validation cohort. Pathologic TNM staging distributions varied widely; 31 (10.4%) individuals had early gastric cancer, and 72 (24.1%) had node negative disease. Two hundred six had died (median follow-up, 989 days) during the follow-up period.

###### Baseline characteristics for training and validation cohort patients

  Clinical characteristics                     Training cohort    Validation cohort   *P*
  -------------------------------------------- ------------------ ------------------- -------
  Age                                          65 (57-74)         66 (57-74)          0.756
  Gender (male)                                352 (73.5)         220 (73.6)          0.977
  Smoking                                      110 (23.0)         56 (18.7)           0.161
  Drinking                                     52 (10.9)          59 (19.7)           0.001
  *Helicobator pylori*                         261 (54.5)         172 (57.5)          0.407
  Tumor differentiation (well/moderate/poor)   89/194/196         40/140/119          0.092
  pT stage (1/2/3/4)                           77/49/199/154      31/25/142/101       0.085
  pN stage (0/1/2/3)                           125/141/97/116     72/110/56/61        0.189
  Metastasis                                   180 (37.6)         127 (42.5)          0.174
  Chemotherapy                                 275 (57.4)         163 (54.5)          0.428
  Curative/palliative                          285/194            161/138             0.121
  TBIL (μmol/L)                                10.1 (7.1-14.6)    9.9 (6.4-13.9)      0.411
  DBIL (μmol/L)                                3.6 (2.5-5.2)      3.5 (2.0-5.4)       0.123
  IBIL (μmol/L)                                6.3 (4.3-9.4)      6.2 (3.5-9.3)       0.078
  Albumin (g/L)                                37.1 (34.1-40.5)   37.2 (33.7-40.0)    0.544

TBIL, Total bilirubin; DBIL, direct bilirubin; IBIL, indirect bilirubin.

Values are medians (interquartile range) or frequencies and percentages.

Patients received treatment for either curative or palliative purposes according to the Japanese Classification of Gastric Cancer Guidelines.

Data were analyzed using χ^2^ test or Mann-Whitney *U* test.

Associations between TBIL, DBIL, IBIL, and albumin levels and clinical characteristics {#s2_2}
--------------------------------------------------------------------------------------

We first compared clinical characteristics of training and validation cohort patients. Patients in the two cohorts were similar with regard to all clinical characteristics except drinking (*P*\<0.001) (Table [1](#T1){ref-type="table"}), indicating that the cohorts were comparable. We then explored associations between TBIL, DBIL, IBIL, and albumin levels and clinical characteristics. X-tile software was used to determine the optimal cutoff values of 5.3 μmol/L for TBIL, 7.3μmol/L for DBIL, 6.7 μmol/L for IBIL, and 33.2 g/L for albumin based on OS in training cohort patients (Figure [1](#F1){ref-type="fig"}). Training cohort patients were then divided into high and low level groups based on these cutoffs. Lymph node metastasis (N2 and N3 stage) was more common in patients in the low TBIL group than in those in the high TBIL group (Table [2](#T2){ref-type="table"}). In addition, markedly more patients in the high DBIL group had T4 and N3 stage disease compared to the low DBIL group (Table [3](#T3){ref-type="table"}). T1 stage and N0 stage disease were more common in patients in the high IBIL group than in those in the low IBIL group (Table [4](#T4){ref-type="table"}). Finally, patients in the high albumin group were younger and more likely to have T1-T2, N0, or M0 stage disease than those in low albumin group (Table [5](#T5){ref-type="table"}). Similar results were obtained when validation cohort patients were divided into high and low level groups for each measure based on the same optimal cutoff values used for the training cohort (Table [2](#T2){ref-type="table"}-[5](#T5){ref-type="table"}).

![X-tile analyses of TBIL (A), DBIL (B), IBIL (C), and albumin (D) levels in training cohort gastric cancer patients\
X-tile plots for training cohort patients are shown in the left panels; black circles highlight the optimal cutoff values, which are also shown in histograms (middle panels). Kaplan-Meier plots are presented in right panels.](oncotarget-08-41305-g001){#F1}

###### Associations between TBIL level and clinical characteristics in training and validation cohort patients

  Variable               TBIL group                                                    
  ---------------------- ------------ ------------ ------- -------------- ------------ -------
  Age                    63 (57-75)   65 (58-74)   0.779   66.5 (57-78)   65 (57-74)   0.173
  Gender                                                                               
   Male                  36 (70.6)    316 (73.8)   0.620   41 (73.2)      179 (73.7)   0.945
   Female                15 (29.4)    112 (26.2)           15 (26.8)      64 (26.3)    
  Smoking                                                                              
   Never                 39 (76.5)    330 (77.1)   0.919   44 (78.6)      199 (81.9)   0.566
   Yes                   12 (23.5)    98 (22.9)            12 (21.4)      44 (18.1)    
  Drinking                                                                             
   Never                 43 (84.3)    384 (89.7)   0.241   45 (80.4)      195 (80.2)   0.985
   Yes                   8 (15.7)     44 (10.3)            11 (19.6)      48 (19.8)    
  *Helicobator pylori*                                                                 
   Negative              21 (41.2)    197 (46.0)   0.511   25 (44.6)      102 (42.0)   0.716
   Positive              30 (58.8)    231 (54.0)           31 (55.4)      141 (58.0)   
  Differentiation                                                                      
   Well                  8 (15.7)     81 (18.9)    0.591   6 (10.7)       34 (14.0)    0.127
   Moderate              24 (47.1)    170 (39.7)           21 (37.5)      119 (49.0)   
   Poor                  19 (37.3)    177 (41.4)           29 (51.8)      90 (37.0)    
  pT stage                                                                             
   T1                    5 (9.8)      72 (16.8)    0.400   1 (1.8)        30 (12.3)    0.001
   T2                    4 (7.8)      45 (10.5)            2 (3.6)        23 (9.5)     
   T3                    26 (51.0)    173 (40.4)           23 (41.1)      119 (49.0)   
   T4                    16 (31.4)    138 (32.2)           30 (53.6)      71 (29.2)    
  pN stage                                                                             
   N0                    10 (19.6)    115 (26.9)   0.017   14 (25.0)      58 (23.9)    0.043
   N1                    12 (23.5)    129 (30.1)           12 (21.4)      98 (40.3)    
   N2                    19 (37.3)    78 (18.2)            14 (25.0)      42 (17.3)    
   N3                    10 (19.6)    106 (24.8)           16 (28.6)      45 (18.5)    
  Metastasis                                                                           
   Absent                30 (58.8)    269 (62.9)   0.575   27 (48.2)      145 (59.7)   0.117
   Present               21 (41.2)    159 (37.1)           29 (51.8)      98 (40.3)    
  Chemotherapy                                                                         
   No                    28 (54.9)    176 (41.1)   0.060   30 (53.6)      106 (43.6)   0.178
   Yes                   23 (45.1)    252 (58.9)           26 (46.4)      137 (56.4)   
  Treatments                                                                           
   Curative              28           257          0.479   25             136          0.125
   Palliative            23           171                  31             107          

TBIL, total bilirubin.

Values are medians (interquartile range) or frequencies and percentages.

Data were analyzed using χ^2^ test or Mann-Whitney *U* test.

###### Associations between DBIL levels and clinical characteristics in training and validation cohort patients

  Variable               DBIL group                                                  
  ---------------------- ------------ ------------ ------- ------------ ------------ -------
  Age                    65 (58-74)   63 (54-74)   0.598   66 (57-74)   62 (52-75)   0.429
  Gender                                                                             
   Male                  308 (72.0)   44 (86.3)    0.029   197 (73.0)   23 (79.3)    0.663
   Female                120 (28.0)   7 (13.7)             73 (27.0)    7 (20.7)     
  Smoking                                                                            
   Never                 331 (77.3)   38 (74.5)    0.650   219 (81.1)   24 (82.8)    0.829
   Yes                   97 (22.7)    13 (25.5)            51 (18.9)    5 (17.2)     
  Drinking                                                                           
   Never                 381 (89.0)   46 (90.2)    0.798   218 (80.7)   22 (75.9)    0.530
   Yes                   47 (11.0)    5 (9.8)              52 (19.3)    7 (24.1)     
  *Helicobator pylori*                                                               
   Negative              193 (45.1)   25 (49.0)    0.595   116 (43.0)   11 (37.9)    0.602
   Positive              235 (54.9)   26 (51.0)            154 (57.0)   18 (62.1)    
  Differentiation                                                                    
   Well                  82 (19.2)    7 (13.7)     0.529   32 (11.9)    8 (27.6)     0.059
   Moderate              174 (40.7)   20 (39.2)            128 (47.4)   12 (41.4)    
   Poor                  172 (40.2)   24 (47.1)            110 (40.7)   9 (31.0)     
  pT stage                                                                           
   T1                    65 (15.2)    12 (23.5)    0.009   30 (11.1)    1 (3.4)      0.014
   T2                    46 (10.7)    3 (5.9)              20 (7.4)     5 (17.2)     
   T3                    187 (43.7)   12 (23.5)            134 (49.6)   8 (27.6)     
   T4                    130 (30.4)   24 (47.1)            86 (31.9)    15 (51.7)    
  pN stage                                                                           
   N0                    112 (26.2)   13 (25.5)    0.005   69 (25.6)    3 (10.3)     0.003
   N1                    135 (31.5)   6 (11.8)             104 (38.6)   6 (20.7)     
   N2                    86 (20.1)    11 (21.6)            49 (18.1)    7 (24.1)     
   N3                    95 (22.2)    21 (41.2)            48 (17.7)    13 (44.8)    
  Metastasis                                                                         
   Absent                273 (63.8)   26 (51.0)    0.074   157 (58.1)   15 (51.7)    0.506
   Present               155 (36.2)   25 (49.0)            113 (41.9)   14 (48.3)    
  Chemotherapy                                                                       
   No                    183 (42.8)   21 (41.2)    0.829   118 (43.7)   18 (62.1)    0.059
   Yes                   245 (57.2)   30 (58.8)            152 (56.3)   11 (37.9)    
  Treatments                                                                         
   Curative              259          26           0.190   147          14           0.527
   Palliative            169          25                   123          15           

DBIL, direct bilirubin.

Values are medians (interquartile range) or frequencies and percentages.

Data were analyzed using χ^2^ test or Mann-Whitney *U* test.

###### Associations between IBIL levels and clinical characteristics in training and validation cohort patients

  Variable               IBIL group                                                  
  ---------------------- ------------ ------------ ------- ------------ ------------ -------
  Age                    66 (59-76)   64 (55-71)   0.078   66 (57-75)   64 (56-73)   0.349
  Gender                                                                             
   Male                  188 (72.3)   164 (74.9)   0.524   131 (77.1)   89 (69.0)    0.117
   Female                72 (27.7)    55 (25.1)            39 (22.9)    40 (31.0)    
  Smoking                                                                            
   Never                 203 (78.1)   166 (75.8)   0.555   139 (81.8)   104 (80.6)   0.802
   Yes                   57 (21.9)    53 (24.2)            31 (18.2)    25 (19.4)    
  Drinking                                                                           
   Never                 233 (89.6)   194 (88.6)   0.718   133 (78.2)   107 (82.9)   0.311
   Yes                   27 (10.4)    25 (11.4)            37 (21.8)    22 (17.1)    
  *Helicobator pylori*                                                               
   Negative              110 (42.3)   108 (49.3)   0.125   72 (42.4)    55 (42.6)    0.961
   Positive              150 (57.7)   111 (50.7)           98 (57.6)    74 (57.4)    
  Differentiation                                                                    
   Well                  44 (16.9)    45 (20.5)    0.593   28 (16.5)    12 (9.3)     0.069
   Moderate              108 (41.5)   86 (39.3)            71 (41.8)    69 (53.5)    
   Poor                  108 (41.5)   88 (40.2)            71 (41.8)    48 (37.2)    
  pT stage                                                                           
   T1                    28 (10.8)    49 (22.4)    0.006   10 (5.9)     21 (16.3)    0.013
   T2                    26 (10.0)    23 (10.5)            15 (8.8)     10 (7.8)     
   T3                    115 (44.2)   84 (38.4)            79 (46.5)    63 (48.8)    
   T4                    91 (35.0)    63 (28.8)            66 (38.8)    35 (27.1)    
  pN stage                                                                           
   N0                    54 (20.8)    71 (32.4)    0.011   36 (21.2)    36 (27.9)    0.003
   N1                    83 (31.9)    58 (26.5)            69 (40.6)    41 (31.8)    
   N2                    62 (23.8)    35 (16.0)            40 (23.5)    16 (12.4)    
   N3                    61 (23.5)    55 (25.1)            25 (14.7)    36 (27.9)    
  Metastasis                                                                         
   Absent                152 (58.5)   147 (67.1)   0.051   96 (56.5)    76 (58.9)    0.672
   Present               108 (41.5)   72 (32.9)            74 (43.5)    53 (41.1)    
  Chemotherapy                                                                       
   No                    115 (44.2)   89 (40.6)    0.428   80 (47.1)    56 (43.4)    0.530
   Yes                   145 (55.8)   130 (59.4)           90 (52.9)    73 (56.6)    
  Treatments                                                                         
   Curative              150          135          0.380   88           73           0.407
   Palliative            110          84                   82           56           

IBIL, indirect bilirubin.

Values are medians (interquartile range) or frequencies and percentages.

Data were analyzed using χ^2^ test or Mann-Whitney *U* test.

###### Association between albumin levels and clinical characteristics in training and validation cohort patients

  Variable               Albumin group                                                    
  ---------------------- --------------- ------------ --------- ------------ ------------ ---------
  Age                    72 (63.5-78)    64 (56-71)   \<0.001   74 (64-78)   64 (56-72)   \<0.001
  Gender                                                                                  
   Male                  71 (70.3)       281 (74.3)   0.414     50 (76.9)    170 (72.6)   0.489
   Female                30 (29.7)       97 (25.7)              15 (23.1)    64 (27.4)    
  Smoking                                                                                 
   Never                 79 (78.2)       290 (76.7)   0.750     54 (83.1)    189 (80.8)   0.673
   Yes                   22 (21.8)       88 (23.3)              11 (16.9)    45 (19.2)    
  Drinking                                                                                
   Never                 91 (90.1)       336 (88.9)   0.728     56 (86.2)    184 (78.6)   0.178
   Yes                   10 (9.9)        42 (11.1)              9 (13.8)     50 (21.4)    
  *Helicobator pylori*                                                                    
   Negative              48 (47.5)       213 (56.3)   0.114     23 (35.4)    104 (44.4)   0.191
   Positive              53 (52.5)       165 (43.7)             42 (64.6)    130 (55.6)   
  Differentiation                                                                         
   Well                  15 (14.9)       74 (19.6)    0.275     9 (13.8)     31 (13.2)    0.922
   Moderate              38 (37.6)       156 (41.3)             29 (44.6)    111 (47.4)   
   Poor                  48 (47.5)       148 (39.2)             27 (41.5)    92 (39.3)    
  pT stage                                                                                
   T1                    8 (7.9)         69 (18.3)    \<0.001   1 (1.5)      30 (12.8)    \<0.001
   T2                    7 (6.9)         42 (11.1)              2 (3.1)      23 (9.8)     
   T3                    36 (35.6)       163 (43.1)             28 (43.1)    114 (48.7)   
   T4                    50 (49.5)       104 (27.5)             34 (52.3)    67 (28.6)    
  pN stage                                                                                
   N0                    15 (14.9)       110 (29.1)   \<0.001   9 (13.8)     63 (26.9)    0.042
   N1                    23 (22.8)       118 (31.2)             27 (41.5)    83 (35.5)    
   N2                    30 (29.7)       67 (17.7)              18 (27.7)    38 (16.2)    
   N3                    33 (32.7)       83 (22.0)              11 (16.9)    50 (21.4)    
  Metastasis                                                                              
   Absent                42 (41.6)       257 (68.0)   \<0.001   23 (35.4)    149 (63.7)   \<0.001
   Present               59 (58.4)       121 (32.0)             42 (64.6)    85 (36.3)    
  Chemotherapy                                                                            
   No                    50 (49.5)       154 (40.7)   0.114     36 (55.4)    100 (42.7)   0.070
   Yes                   51 (50.0)       224 (59.3)             29 (44.6)    134 (57.3)   
  Treatments                                                                              
   Curative              53              232          0.106     30           131          0.160
   Palliative            48              146                    35           103          

Values are medians (interquartile range) or frequencies and percentages.

Data were analyzed using χ^2^ test or Mann-Whitney *U* test.

Prognostic significance of TBIL, DBIL, IBIL, and albumin {#s2_3}
--------------------------------------------------------

Five-year overall survival rates and univariate log-rank test results for clinical variables in the training and validation cohorts are shown in Table [6](#T6){ref-type="table"}. Five-year OS was shorter in patients with low TBIL, IBIL, and albumin levels (*P*\<0.01). Multivariate Cox regression analysis was then conducted for clinical features identified as significant in the univariate log-rank test. T, N, and M stages as well as TBIL and albumin levels were independently prognostic factors for OS in both the training and validation cohorts (Table [6](#T6){ref-type="table"}).

###### Univariate and multivariate analyses of prognostic significance of serum bilirubin and albumin levels

                         Training cohort   Validation cohort                                                                                              
  ---------------------- ----------------- ------------------- --------- --------------------- --------- ------ --------- --------- --------------------- ---------
  Age                                      3.543               0.060                                            2.379     0.121                           
   \<65 years            42.4                                                                            34.1                                             
   ≥65 years             33.7                                                                            28.1                                             
  Gender                                   1.552               0.213                                            0.361     0.548                           
   Male                  36.7                                                                            29.8                                             
   Female                40.9                                                                            32.7                                             
  Smoking                                  1.683               0.195                                            0.338     0.561                           
   Never                 35.7                                                                            31.2                                             
   Yes                   45.0                                                                            27.8                                             
  Drinking                                 0.949               0.330                                            0.580     0.446                           
   Never                 37.1                                                                            29.7                                             
   Yes                   43.4                                                                            34.2                                             
  *Helicobator pylori*                     1.521               0.218                                            0.001     0.972                           
   Negative              34.2                                                                            28.8                                             
   Positive              40.8                                                                            31.8                                             
  Differentiation                          33.100              \<0.001                                          18.475    \<0.001                         
   Well                  64.0                                            Reference                       57.7                       Reference             
   Moderate              34.7                                            1.028 (0.710-1.577)   0.692     30.7                       1.442 (0.819-2.539)   0.205
   Poor                  29.1                                            1.147 (0.600-1.668)   0.823     22.4                       1.617 (0.924-2.828)   0.092
  pT stage                                 153.793             \<0.001                                          96.193    \<0.001                         
   T1                    87.0                                            Reference                       80.6                       Reference             
   T2                    66.0                                            1.022 (0.962-3.605)   0.068     42.9                       1.896 (1.232-2.833)   0.011
   T3                    30.7                                            1.920 (1.041-4.224)   0.012     32.1                       1.937 (1.181-3.280)   0.003
   T4                    13.5                                            2.446 (1.253-5.233)   \<0.001   9.9                        2.341 (1.214-3.676)   \<0.001
  pN stage                                 190.446             \<0.001                                          58.345    \<0.001                         
   N0                    80.2                                            Reference                       63.9                       Reference             
   N1                    36.6                                            1.387 (1.056-2.900)   0.043     29.7                       1.735 (1.013-2.973)   0.045
   N2                    17.5                                            2.006 (1.310-4.018)   \<0.001   18.0                       2.150 (1.182-3.911)   0.012
   N3                    10.3                                            3.043 (1.085-6.364)   \<0.001   9.8                        2.609 (1.451-4.693)   \<0.001
  Metastasis                               160.020             \<0.001                                          144.813   \<0.001                         
   Absent                53.7                                            Reference                       45.5                       Reference             
   Present               11.6                                            1.859 (1.254-2.706)   \<0.001   7.8                        2.168 (1.407-3.154)   \<0.001
  Chemotherapy                             0.109               0.742                                            0.168     0.682                           
   No                    40.7                                                                            30.2                                             
   Yes                   37.8                                                                            30.9                                             
  Treatments                               98.528              \<0.001                                          120.314   \<0.001                         
   Curative              50.6                                            Reference                       42.7                       Reference             
   Palliative            15.0                                            1.556 (1.160-2.011)   \<0.001   9.4                        2.590 (1.423-3.154)   \<0.001
  TBIL (μmol/L)                            7.613               0.006                                            31.756    \<0.001                         
   ≤5.3                  23.5                                            Reference                       7.9                        Reference             
   \>5.3                 39.5                                            0.688 (0.491-0.959)   0.022     36.1                       0.794 (0.552-0.951)   0.032
  DBIL (μmol/L)                            2.204               0.138                                            0.097     0.756                           
   ≤7.3                  38.8                                                                            30.0                                             
   \>7.3                 29.4                                                                            36.1                                             
  IBIL (μmol/L)                            9.818               0.002                                            5.099     0.024                           
   ≤6.7                  30.8                                            Reference                       25.0                       Reference             
   \>6.7                 46.1                                            0.994 (0.792-1.290)   0.860     37.9                       0.915 (0.662-1.264)   0.590
  Albumin (g/L)                            23.351              \<0.001                                          17.036    \<0.001                         
   ≤33.2                 22.8                                            Reference                       20.2                       Reference             
   \>33.2                41.8                                            0.685 (0.520-0.890)   0.002     33.4                       0.774 (0.554-0.961)   0.034

TBIL, Total bilirubin; DBIL, direct bilirubin; IBIL, indirect bilirubin. HR, hazard ratio; CI, confidence interval.

Nomogram for predicting gastric cancer outcomes {#s2_4}
-----------------------------------------------

To further assess the predictive ability of TBIL and albumin in gastric cancer patients, we used a nomogram based on the results of the univariate analyses to predict 5-year overall survival rates. Tumor grade, T, N, and M stage, treatment approach, and TBIL, IBIL, and albumin level were included in the nomogram for both the training (Figure [2A](#F2){ref-type="fig"}) and validation (Figure [2B](#F2){ref-type="fig"}) cohorts. The predictive models for both cohorts showed that treatment with palliative operation and advanced T, N, and M stage were poor prognostic indicators, while high TBIL and albumin levels were favorable factors. These findings were similar to those obtained previously in the multivariate Cox regression analyses (Table [6](#T6){ref-type="table"}). Calibration curves for the nomogram in both cohorts revealed that the predicted 5-year OS values were similar to the actual 5-year OS (Figure [2C](#F2){ref-type="fig"} and [2D](#F2){ref-type="fig"}).

![Nomogram for predicting gastric cancer outcomes\
The sum of the points assigned to each factor by the nomogram is shown at the top of scale. Total point values were used to predict 5-year probability of death in the lowest scale. The c-indexes values for the training cohort **(A)** and the validation cohort **(B)** are 0.762 and 0.744, respectively. Calibration curves for 5-year OS, which are indicative of predictive accuracy, for the training cohort **(C)** and the validation cohort **(D)**. The 45-degree reference line represents a perfect match between observed and predicted values.](oncotarget-08-41305-g002){#F2}

We then compared the predictive accuracy of the nomogram to that of the TNM staging system (T, N, and M stage only) in the training and the validation cohorts using Harrell\'s c-index. The Harrell\'s c-index values for the nomogram in the training and the validation cohorts were 0.774 and 0.760, respectively, compared to 0.727 and 0.702, respectively, for the TNM staging system. Collectively, the predictive accuracy of the nomogram based on TBIL and albumin levels was better than that of the TNM staging system in both patient cohorts (*P*\<0.01).

DISCUSSION {#s3}
==========

In this study, we confirmed the prognostic significance of serum bilirubin and albumin levels and, to our knowledge, demonstrated for the first time that elevated pre-treatment levels of these factors were positive prognostic factors for survival in gastric cancer. Elevated TBIL and albumin levels were associated with tumor progression and acted as protective prognostic factors in both training and validation cohort gastric cancer patients. Our nomogram also confirmed the prognostic significance of TBIL and albumin in gastric cancer patients.

Bile acid, which is the end product of cholesterol breakdown, exists in three forms in peripheral blood: TBIL, DBIL, and IBIL. Due to its anti-inflammation, antioxidant, and antiproliferation effects, bilirubin acts as a protective factor against carcinogenesis \[[@R12]\]. Decreased serum bilirubin is associated with an increased risk of cancer and with poorer outcomes \[[@R7]\]. Li *et* *al*. demonstrated that non-small cell lung cell cancer patients with higher pretreatment bilirubin levels had longer OS, DFS, and DMFS than those with lower levels \[[@R8]\]. Zhang and colleagues also found that high DBIL was strongly associated with worse outcomes after surgery in colorectal cancer patients with stage II and stage III disease in a retrospective study \[[@R9]\]; subsequent studies confirmed these results \[[@R13], [@R14]\]. However, the association between serum bilirubin levels and clinical outcomes in gastric cancer had not been examined. Here, we found that decreased serum TBIL was associated with advanced gastric cancer and poor prognosis, as is the case in other types of cancer \[[@R8], [@R9], [@R15]\]. Although training and validation cohort patients in our study differed with regard to drinking behavior, correlation analysis revealed no association between drinking status and serum bilirubin and albumin levels. Furthermore, serum TBIL and albumin were independent prognostic indicators regardless of drinking status both in the training and the validation cohorts. Taken together, these results suggest that serum bilirubin may have predictive value in gastric cancer.

Serum albumin, which is commonly used to evaluate an individual\'s nutritional status, also has antioxidant effects and acts as a transporter of key nutrients. Serum albumin levels fall sharply in patients with advanced cancer due to malnutrition and systemic inflammatory responses to malignancy \[[@R16]\]. Malnutrition can also cause a series of detrimental clinical effects and thus reduce treatment response. Previous studies have assessed the association between serum albumin and survival in gastric cancer patients \[[@R17], [@R18]\]. Liu *et* *al*. reported that serum albumin was an independent prognostic factor for worse outcomes in 1320 gastric cancer patients after curative resection \[[@R19]\]. In a separate study of 320 gastric cancer patients, Liu *et* *al*. found that preoperative albumin, BMI, and triglyceride levels were more accurate for predicting survival than the TNM system \[[@R20]\]. Our findings strongly suggest that low serum albumin levels are a prognostic indicator of poor outcome in gastric cancer patients, which is consistent with previous findings for other malignancies \[[@R21], [@R22]\].

Although individual serum markers are useful prognostic factors in studies of cancer patients, single markers may not be adequate for predicting survival in a clinical setting. Combining several markers in a single index may improve their predictive power \[[@R23]--[@R25]\], and nomograms are a useful method for combining clinical characteristics to improve survival predictions for individual patients. In the current study, we constructed a nomogram to predict survival in training and validation cohort gastric cancer patients based on several clinical characteristics. The nomogram accurately predicted 5-year overall survival in the training and validation cohorts; Harrell\'s c-indexes confirmed the accuracy of these predictions. Furthermore, serum TBIL and albumin levels were incorporated into the nomogram using a stepwise algorithm, and the predictive ability of the nomogram was confirmed using calibration curves. Additionally, a comparison of the predictive abilities of the constructed nomogram and the TNM staging system revealed that the nomogram was superior to TNM in both cohorts.

A major strength of this study is that it involved a relatively large number of gastric cancer patients undergoing treatment at a single center and that it included both prospective and retrospective cohorts. However, external validation studies should be performed to determine whether our results are applicable in other patient populations \[[@R26]\]. Another strength of this study is the use of X-tile software, which is a robust graphical tool \[[@R27]\], to determine the optimal cutoff values for serum bilirubin and albumin levels. However, some limitations should be considered when interpreting these results. For example, only pretreatment serum bilirubin and albumin levels were included in the present analyses, and it is possible that dynamic changes in serum bilirubin and albumin levels during the course of treatment might also influence outcomes in gastric cancer patients.

In summary, in this study of 778 gastric cancer patients, we found that a nomogram based on serum TBIL and albumin levels was more accurate than the TNM staging system in predicting survival. These findings suggest that serum TBIL and albumin levels in combination might improve outcome predictions for gastric cancer patients.

MATERIALS AND METHODS {#s4}
=====================

Study population {#s4_1}
----------------

The patients involved in this study were divided among two cohorts. The prospective training cohort consisted of 479 patients who underwent surgical resection or chemotherapy at the Nanjing First Hospital, Nanjing Medical University between January 2010 and November 2012. The retrospective validation cohort consisted of 299 patients who underwent surgical resection or chemotherapy at the same institution between January 2006 and December 2009. All individuals were diagnosed with biopsy-proven gastric adenocarcinoma. Patients who died within 30 days of surgery or who received preoperative antitumor treatment were excluded. Patients with tumors that invaded the biliary tract were also excluded due to the resulting elevation of serum bilirubin levels. All individuals received either open or laparoscopic surgery for either curative or palliative purposes according to the Japanese Classification of Gastric Cancer Guidelines \[[@R28]\]. Detailed clinical characteristics were collected before cancer treatment. Individuals were restaged according to the 7^th^ edition of the American Joint Committee on Cancer staging system.

Regular follow-ups, which occurred every 3 months for the first 2 years and then every 6 months for 3 more years, began after the date of treatment and continued until September 30, 2016 or until patient death. Routine examination, gastroscopy, and imaging were performed at every visit. The follow-up period ranged from 91 to 3535 days, with a median of 1026 days. The study was approved by the Institutional Review Board of Nanjing First Hospital. Informed consent for use of their data was obtained from training cohort patients because of the prospective nature of the study.

Detection of serum bilirubin and albumin {#s4_2}
----------------------------------------

Blood samples were collected from patients and serum was separated by centrifugation. Serum albumin levels were measured using a Roche Modular D/P automated analyzer (Roche, USA). Serum bilirubin levels were determined using the vanadium oxidation method.

Statistical analysis {#s4_3}
--------------------

Data assessment was performed using SPSS 20.0 version (SPSS Inc., Chicago, IL, USA) and R 3.3.1 software (Institute for Statistics and Mathematics, Vienna, Austria). First, optimal cutoff values for total bilirubin (TBIL), direct bilirubin (DBIL), indirect bilirubin (IBIL), and albumin levels were determined using X-tile 3.6.1 software (Yale University, New Haven, CT, USA) \[[@R27]\]. Differences between high- and low-level group patients were evaluated using the χ^2^ test or Mann-Whitney *U* test. Survival analysis was performed using the Kaplan-Meier curve and log-rank test. Significant prognostic predictors from the survival analysis were included in a multivariate analysis using the Cox proportional hazards model. The nomogram for significant factors associated with 5-year overall survival (OS) was constructed using R software via a stepwise algorithm, and Harrell\'s concordance index (c-index) was used to compare the performance of the nomogram to that of the TNM staging system. A calibration curve comparing observed outcomes to predicted outcomes was generated to further evaluate the nomogram\'s accuracy in predicting prognosis. *P* values of less than 0.05 were regarded as statistically significant.
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